Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.78 USD | -0.27% | -8.93% | +53.64% |
Apr. 26 | B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target | MT |
Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 64% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+53.64% | 925M | C+ | ||
-3.46% | 102B | B+ | ||
+1.41% | 96.09B | B+ | ||
+2.13% | 22.28B | B | ||
-15.84% | 21.4B | B+ | ||
-9.21% | 18.14B | A- | ||
-39.98% | 17.02B | A- | ||
-14.65% | 16.09B | B | ||
+4.39% | 13.83B | C+ | ||
+31.35% | 11.97B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MGNX Stock
- Ratings MacroGenics, Inc.